Medtronic plc — Form 10-Q summary
Reporting period: Third quarter and first nine months of fiscal 2020, ended January 24, 2020; comparisons are to periods ended January 25, 2019. The filing metadata’s “2019 Q3” label does not match the fiscal period stated in the filing. Amounts are in U.S. dollars; financial statement amounts are in millions unless noted.
Business context and results
Medtronic is a global medical technology company reporting four segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. Third-quarter net sales rose 2% to $7.717 billion; nine-month sales rose 2% to $22.916 billion.
| Metric | Three months | Nine months |
|---|---|---|
| Net sales | $7.717B, up 2% | $22.916B, up 2% |
| Operating profit | $1.639B vs. $1.542B | $4.475B vs. $4.322B |
| Operating margin | 21.2% vs. 20.4% | 19.5% vs. 19.3% |
| Net income attributable to Medtronic | $1.915B vs. $1.269B | $4.143B vs. $3.459B |
| Diluted EPS | $1.42 vs. $0.94 | $3.07 vs. $2.54 |
| Operating cash flow | Not presented for quarter alone | $5.784B vs. $4.920B |
| Free cash flow | Not presented for quarter alone | $4.907B vs. $4.121B |
Gross margin declined to 68.9% from 70.0% for the quarter and to 68.8% from 70.2% year to date. Management cited restructuring costs, higher duties including China tariffs, and, for the nine-month period, costs to address a sterilization shortage. SG&A as a share of sales improved; R&D as a share of sales was unchanged.
Segments and material changes
- Cardiac and Vascular: Third-quarter sales increased 1% to $2.819B; nine-month sales were essentially flat at $8.464B. Coronary and structural heart products grew, while cardiac rhythm and heart failure faced declines, including ICD/CRT-D replacement-cycle and LVAD competitive pressures.
- Minimally Invasive Therapies: Sales increased 2% to $2.176B for the quarter and 3% to $6.418B year to date. U.S./Canada ERP implementation temporarily slowed supply and contributed to lost procedures.
- Restorative Therapies: Sales increased 4% to $2.111B for the quarter and 5% to $6.235B year to date. Brain Therapies was a growth driver; Pain Therapies declined amid a U.S. spinal cord stimulation market slowdown.
- Diabetes: Quarterly sales were flat at $610M; nine-month sales increased 2% to $1.798B. International growth was offset in the quarter by U.S. competition and declines.
Emerging-market sales grew 12% in the quarter and 10% year to date. Foreign currency reduced sales by $46M for the quarter and $289M year to date. Prior-year Restorative Therapies division results were recast following a realignment.
Liquidity, debt, and capital allocation
At January 24, 2020, cash and cash equivalents were $3.709B and current investments were $7.919B, together $11.628B; total current assets were $24.043B and current liabilities $8.735B. Total debt was approximately $25.6B, including $0.844B current and $24.732B long-term, versus approximately $25.3B at April 26, 2019. The $3.5B revolving credit facility was undrawn, with no commercial paper outstanding. Management said available liquidity was expected to cover foreseeable operating needs for at least 12 months.
Nine-month cash used in investing was $3.568B, including $8.249B of investment purchases and $5.791B of sales and maturities; cash used in financing was $2.888B. The company issued €5.0B of notes for approximately $5.6B and used proceeds in a debt tender and redemptions. It recorded a $413M extinguishment loss, contributing to nine-month interest expense of $930M versus $726M. Dividends were $2.170B and share repurchases $1.208B for the nine months.
Outlook, risks, and unusual items
- COVID-19: Management expected a negative fourth-quarter impact from delayed procedures in China and warned of possible supply interruptions. It said the duration and magnitude were difficult to assess; China represented approximately 7% of company revenue.
- Restructuring: Enterprise Excellence is expected to generate more than $3.0B in annual gross savings by fiscal 2022, with approximately $500M–$700M expected each fiscal year through then. Estimated pretax charges are $1.6B–$1.8B, mostly by fiscal 2022; cash outlays are expected to be substantially complete by fiscal 2023. Nine-month charges were $328M.
- Taxes: A $558M quarterly tax benefit from releasing a valuation allowance on certain Luxembourg-related net operating losses materially boosted reported earnings. Nine-month tax adjustments provided a net $839M benefit. The reported effective tax rates were negative 21.5% for the quarter and negative 8.2% year to date; non-GAAP nominal rates were 13.6% and 14.5%.
- Legal and regulatory exposure: Accrued litigation was approximately $0.6B, up from $0.5B at fiscal year-end; nine-month litigation charges were $276M. The company cautioned that ultimate costs could differ materially. Significant matters include pelvic mesh claims, a patent/royalty dispute, environmental remediation, government inquiries, and tax disputes. Gross unrecognized tax benefits were $1.8B.
- Other risks include competition and pricing pressure, reimbursement changes, procedure volumes, product launches and approvals, currency movements, supply continuity, and litigation outcomes. No specific full-year sales or EPS guidance is stated in the supplied filing text.
Key facts for investors to verify
- Whether the Luxembourg tax benefit and planned intercompany intellectual-property transaction support the expected use of the relevant tax losses.
- The duration and financial effects of COVID-19-related procedure delays and potential supply disruptions.
- Progress on Enterprise Excellence savings relative to its remaining restructuring costs and cash requirements.
- Developments in accrued litigation, the IRS/Puerto Rico transfer-pricing disputes, and other tax contingencies.
- Underlying segment growth and margins excluding currency effects, ERP-related disruption, and significant tax or other unusual items.